SCM
KYMR icon

Sterling Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Sterling Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46K Buy
401
+30
+8% +$2.58K ﹤0.01% 1604
2026
Q1 		$30.9K Hold
371
– – ﹤0.01% 1831
2025
Q4 		$28.9K Buy
371
+249
+204% +$16.8K ﹤0.01% 2034
2025
Q3 		$6.91K Buy
122
+8
+7% +$361 ﹤0.01% 2660
2025
Q2 		$4.97K Buy
114
+65
+133% +$2.24K ﹤0.01% 2518
2025
Q1 		$1.34K Hold
49
– – ﹤0.01% 2719
2024
Q4 		$1.97K Buy
49
+3
+7% +$135 ﹤0.01% 2790
2024
Q3 		$2.18K Buy
+46
New +$2.03K ﹤0.01% 2144

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Sterling Capital Management's KYMR Position: Q2 2026 in Review

Sterling Capital Management increased its Kymera Therapeutics (KYMR) stake by 8.1% in Q2 2026, buying an estimated $2.58K and bringing the position to 401 shares worth $46K. The position accounts for ﹤0.01% of the portfolio, ranked #1604.

Sterling Capital Management first reported a position in KYMR in Q3 2024 and has held it in 8 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Sterling Capital Management held 401 shares of Kymera Therapeutics worth $46K as of Q2 2026.
  • Sterling Capital Management bought 30 Kymera Therapeutics shares in Q2 2026, an estimated $2.58K.
  • Kymera Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1604 holding.
  • Sterling Capital Management first reported a position in Kymera Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.